CELEXT07

9305-9954 Quebec Inc · Phase 2 active Small molecule

At a glance

Generic name	CELEXT07
Sponsor	9305-9954 Quebec Inc
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CELEXT07 CI brief — competitive landscape report
CELEXT07 updates RSS · CI watch RSS
9305-9954 Quebec Inc portfolio CI